Canaccord Genuity Rates Tango Therapeutics (TNGX) buy
Canaccord Genuity reiterated its buy rating on TNGX, setting a price target of $42, up from a previous target of $42, a 40.89% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Canaccord Genuity rated Tango Therapeutics, Inc. ($TNGX) "buy" with a $42 price target on June 11, 2026.
Since the rating, $TNGX is down 6.2% after 1 week, down 4.9% after 1 month and down 26.1% to date (from the $29.82 close on Jun 11, 2026).
TNGX
Tango Therapeutics, Inc.
Key Points
- On June 11, 2026, Canaccord Genuity reiterated its buy rating on TNGX, setting a price target of $42.0.
- Canaccord Genuity's $42 price target implies 40.89% upside from Tango Therapeutics, Inc.'s ($TNGX) current $29.81 share price.
- The stock recently closed at $29.81, up from its previous close of $21.75, reflecting strong investor interest.
- Tango Therapeutics has a market cap of about $3.77 billion, with analysts generally recommending a strong buy.
Get $TNGX trade alerts by text
We text you when insiders, Congress or big funds trade $TNGX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Tango Therapeutics, Inc. alert may contain errors. Disclosures
Canaccord Genuity's Continued Confidence in TNGX
On June 11, 2026, Canaccord Genuity reiterated its buy rating on Tango Therapeutics, Inc. (TNGX) on the NasdaqGM, maintaining a price target of $42.0. The stock was trading at $29.81, which shows a notable increase from its previous close of $21.75.
Rating Comparison with Wall Street
This recent rating from Canaccord Genuity comes as part of a broader positive outlook from other analysts on TNGX. The firm has consistently kept its buy rating on Tango, signaling confidence in the company’s growth prospects. While Canaccord has increased its price target, it follows a trend among various other analysts who have been closely monitoring TNGX.
Analysts Set New Price Targets
Several firms have weighed in on TNGX recently. On June 26, 2026, Jefferies upgraded its rating to buy, raising its target to $60.0 from $27.0. On July 15, 2026, JP Morgan initiated coverage with an overweight rating and a target of $46.0. Meanwhile, on August 12, 2026, Guggenheim maintained its buy rating but raised its target to $35.0 from $32.0. Overall, the consensus among analysts shows strong faith in TNGX's future, with a mean price target of about $45.18 based on 11 analyst opinions.
Stock Performance Insights
Currently, TNGX trades significantly above its 52-week low of $6.69, indicating a strong recovery in price. Its performance has been buoyed by positive sentiment surrounding its pipeline of oncology treatments. The stock has also shown volatility, with a beta of 1.12, suggesting it moves with the market trends.
$TNGX price target
Tango Therapeutics, Inc. daily closes and this analyst's $42 target. Not advice.
What TNGX Does
Tango Therapeutics, Inc. focuses on developing precision oncology drugs tailored to specific patient populations. The company is working on several promising therapies, including PRMT5 inhibitors for pancreatic and lung cancers, and co-repressors for lung cancer immunotherapy.
What to Watch at TNGX
The next earnings report for Tango Therapeutics is scheduled for November 4, 2026, which could provide further insights into the company's financial health and progress on its drug development. As the market continues to respond to analyst ratings, investors should keep an eye on upcoming filings and additional analyst coverage.
Related Filing Alerts
Source: Canaccord Genuity's rating change on $TNGX (Jun 11, 2026). Written by software, not financial advice. How we make alerts